Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy

NCT00595335 is registered in ClinicalTrials.gov with Rebecca Bahn as lead sponsor.

NCT NCT00595335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00595335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy
Lead sponsor
Rebecca Bahn
Phase
Phase 2/3
Overall status
Completed
Start date
April 30, 2008
Completion date
September 30, 2013
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid-associated ophthalmopathy